Pharma BD Deal Intelligence
Luminex Corporation acquired GenturaDx in a $50 million transaction to expand its capabilities in molecular diagnostics and laboratory testing technologies for…
signed on its behalf by the undersigned hereunto duly authorized.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Luminex Corporation acquired GenturaDx for $50 million in cash to expand its molecular diagnostics platform, adding GenturaDx's sample-to-answer real-time PCR and MultiCode-RTx chemistry.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GenturaDx / LUMINEX CORP (this deal) | 2012 | $50M | 48 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2012 deals · Infectious Disease deals